Repare Therapeutics to Attend Goldman Sachs 45th Annual Global Healthcare Conference

Repare Therapeutics Inc., a prominent company in the field of precision oncology, has announced that its senior management team will be participating in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled to take place on June 10, 2024, at 2:40 p.m. Eastern Time in Miami, FL. The discussion will be accessible via a live webcast, which can be found on the Investor section of Repare's website. For those unable to attend the live session, a replay will be available on the website for 90 days.

Repare Therapeutics, based in Cambridge, Mass. and Montreal, is at the forefront of developing precise cancer treatments through its innovative synthetic lethality approach. This method focuses on exploiting specific vulnerabilities in cancer cells by targeting genomic instability and DNA damage repair mechanisms. The company's proprietary SNIPRx® platform, which leverages CRISPR technology, plays a critical role in the discovery and development of these targeted therapies.

The company's current pipeline is robust and diverse, featuring several promising candidates at various stages of development. Lunresertib, also known as RP-6306, is a PKMYT1 inhibitor presently in Phase 1/2 clinical trials. This compound is designed to interfere with a key enzyme involved in cell cycle regulation, thereby inhibiting the growth of cancer cells. Camonsertib, also referred to as RP-3500, is another key candidate in Phase 1/2 trials. As a potential leading ATR inhibitor, it aims to exploit cancer cell's reliance on the ATR pathway for survival under conditions of DNA damage.

Another notable candidate is RP-1664, a PLK4 inhibitor that is currently in Phase 1 development. PLK4 is an enzyme that plays a critical role in cell division, and inhibiting it could potentially halt the proliferation of cancer cells. In the preclinical stage, the company's pipeline includes RP-3467, a Polθ ATPase inhibitor. This program targets the Polθ enzyme, which is involved in an alternative DNA repair pathway that cancer cells might rely on, particularly when other repair mechanisms are compromised.

Repare Therapeutics continues to advance additional preclinical programs, which are currently undisclosed. These programs are expected to further expand the company's portfolio of targeted cancer therapies.

The SNIPRx® platform, central to Repare's discovery efforts, allows for a systematic and comprehensive approach to identifying synthetic lethal interactions. By employing genome-wide CRISPR screening, the platform can pinpoint specific genetic interactions that can be therapeutically targeted, thereby providing a pipeline of novel cancer treatments.

Repare's innovative approach and promising pipeline underscore its commitment to developing next-generation cancer therapies. The participation of its senior management in the upcoming healthcare conference reflects the company's ongoing engagement with the broader scientific and investment communities, aiming to highlight its progress and future directions in precision oncology.

In summary, Repare Therapeutics is making significant strides in the field of precision oncology through its synthetic lethality approach and CRISPR-enabled SNIPRx® platform. With a diverse pipeline featuring compounds at various stages of clinical and preclinical development, the company is well-positioned to bring new, targeted therapies to patients with cancer.